The Netherlands: Europe's Quiet Powerhouse of Clinical Innovation

With 31 commercial sponsors and 138 active trials launching in 2026, the Dutch research ecosystem is signalling something remarkable.

Few countries punch above their weight in life sciences quite like the Netherlands. In 2026 alone, 138 active clinical trials, spanning oncology, neurology, rare diseases, metabolic disorders, are under way or imminent on Dutch soil, with no fewer than 31 commercial sponsors choosing the country as a home for their research programmes. That is not a coincidence. It is the result of decades of deliberate investment in infrastructure, talent, and a regulatory culture that genuinely welcomes innovation.

The breadth of therapeutic ambition on display is striking. Boehringer Ingelheim, one of the most prolific commercial sponsors in the current Dutch market, is running multiple Phase 3 programmes simultaneously, from the TRPC6 inhibitor BI 764198 targeting proteinuric kidney diseases, to nerandomilast in fibrosing interstitial lung diseases, to the DAREON-Lung-1 study in extensive-stage small cell lung cancer. That a single sponsor can anchor so many late-stage trials within one national ecosystem speaks volumes about the depth of clinical capacity here.

The Netherlands is not merely participating in global drug development - it is shaping it, hosting pivotal studies that will determine the standard of care for millions of patients worldwide.

Oncology dominates the landscape, as it does globally, but what sets the Netherlands apart is the sophistication of its trial design. Bristol-Myers Squibb has chosen Dutch sites for both ROSETTA Lung-201 and ROSETTA Lung-202, two landmark Phase 3 studies evaluating pumitamig as a potential new immunotherapy standard in non-small cell lung cancer. Meanwhile, IDEAYA Biosciences is running OptimUM-10, a neoadjuvant darovasertib trial in uveal melanoma, a disease so rare that recruiting even a handful of the right patients demands exceptional specialist networks. The Netherlands, evidently, has them.

Amsterdam Canal

Beyond oncology, the commercial appetite for Dutch clinical sites spans an impressively wide arc. Eli Lilly is executing two simultaneous Phase 3 baricitinib studies in Type 1 diabetes prevention and beta-cell preservation. Novo Nordisk is not only running the CagriSema paediatric obesity programme but also pursuing a novel PET imaging study for transthyretin amyloid cardiomyopathy. Medtronic Diabetes is launching its NMX8 automated insulin delivery system study here. The pattern is consistent: where science is hard and patients are complex, global sponsors increasingly turn to the Netherlands.

Smaller biotechs are also active, and perhaps even more telling of the ecosystem's health. Dutch companies Khondrion BV, Citryll BV, and EBI Anti Sepsis BV are each sponsoring trials of their own, a sign that the country is not merely hosting international capital but generating its own. First-in-human studies from Basilea Pharmaceutica, AC Immune SA, and QurAlis Corporation further reinforce the Netherlands as a preferred destination for early-phase discovery work, where trust between sponsor and site is paramount.

What makes all of this possible? A combination of factors that is genuinely difficult to replicate. The Netherlands benefits from a highly educated, multilingual patient population with strong historical participation rates in clinical research. Its regulatory and ethics review processes are efficient without being permissive. Academic medical centres; from Amsterdam UMC to Erasmus MC, Radboud UMC to Maastricht UMC, operate at a standard that global sponsors trust implicitly, providing the infrastructure through which commercial partners can enrol, monitor, and deliver results at pace.

The outlook for the remainder of 2026 and into 2027 is, if anything, even more promising. Several of the trials currently listed as "not yet recruiting" — including Biosense Webster's VARIPULSE Pro atrial fibrillation studies, Medtronic's NMX8 programme, and Boehringer Ingelheim's systemic sclerosis Phase 3, are due to open imminently, adding further momentum to an already exceptional year. The Netherlands is not merely participating in global drug development. It is, quietly and systematically, helping to lead it.

---

COG Europe

Location: Amsterdam, Netherlands

Audience Catchment: Clinical executives from across Europe, including biopharma industry leaders, regulatory bodies, and academic contributors from the EU and wider European continent.

Key Themes Discussed: COG Europe serves as the premier meeting place for senior executives across the European clinical trial sector. The 2026 event features a CEO panel with chief executives discussing strategies for funding clinical development, including international trends and cross-border partnerships.

The conference covers multiple agenda streams over two days, addressing:

• Clinical trial outsourcing strategies and vendor management

• Operations and technology innovation

• Supply chain and logistics management

• Regulatory developments across European markets

• International collaboration and partnership opportunities

The event brings together large and small/emerging biopharma companies, creating opportunities for active networking and discussion that deliver real takeaway value for all attendees.

Find out more: https://www.thepbcgroup.com/cog-europe